Complete resolution of transplantation-associated thrombotic microangiopathy and hepatic veno-occlusive disease by defibrotide and plasma exchange

Turkish Journal of Gastroenterology

Volumn 16, Issue 1, 2005, Pages 34-37

  Kalayoglu Besisik, Sevgi ^a,b   Bahat Öztürk, Gülistan ^a   Çalişkan, Yaşar ^a   Sargin, Deniz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cell transplantation; Defibrotide; Hepatic veno occlusive disease; Thrombotic microangiopathy

Indexed keywords

ACICLOVIR; BILIRUBIN; BUSULFAN; CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFIBROTIDE; FLUCONAZOLE; HEMOGLOBIN; ISEPAMICIN; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PHENYTOIN; URSODEOXYCHOLIC ACID; VANCOMYCIN;

ABDOMINAL DISTENSION; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASCITES; ATELECTASIS; B CELL LYMPHOMA; BILIRUBIN BLOOD LEVEL; BLOOD SMEAR; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; GRAFT VERSUS HOST REACTION; HEMOFILTRATION; HEMORRHAGIC CYSTITIS; HEPATIC VEIN; HEPATOMEGALY; HUMAN; INTENSIVE CARE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER VEIN OBSTRUCTION; LYMPHOBLASTOMA; MALE; NEPHROTOXICITY; OLIGURIA; PLASMAPHERESIS; PLEURA EFFUSION; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRESSURE GRADIENT; PROPHYLAXIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA;

ADULT; FOLLOW-UP STUDIES; HEPATIC VEIN THROMBOSIS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LYMPHOMA, B-CELL; MALE; MICROCIRCULATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMA EXCHANGE; PLATELET AGGREGATION INHIBITORS; POLYDEOXYRIBONUCLEOTIDES;

EID: 17644415368     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bearman SI, Shuhart MC, Hinds MS, et al. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-62.
2. Bearman SI, Lee JL, Baron AE, et al. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-6.
3. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993; 45: 259-94.
4. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-44.
5. Zager RA. Acute renal failure in the setting of bone marrow transplantation. Kidney Int 1994; 46: 1443-58.
6. Uderzo C, Fumagalli M, De Lorenzo P, et al. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1005-9.
7. Corti P, Uderzo C, Tagliabue A, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002; 29: 542-3.
8. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.
9. Rio P, Andreu G, Nicod A, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67: 1773-6.
10. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-20.
11. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
12. Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-36.
13. Pescador R, Porta R, Ferro L. An integrated view of the activities of defibrotide. Semin Thromb Hemost 1996; 22: 71-5.
14. Iacopino P, Pucci G, Arcese W, et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999; 24: 47-51.
15. Van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-802.
16. Schriber JR, Herzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997; 34: 126-33.
17. Zeigler ZR, Shadduck RK, Nemunaitis J, et al. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995; 15: 247-53.
18. Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996; 94: 383-6.
19. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-9.
20. Mor E, Pappo O, Bar-Nathan N, et al. Defibrotide for the treatment of veno-occlusive disease after liver transplantation. Transplantation 2001; 72: 1237-40.
21. Ben-Ari Z. Life-threatening veno-occlusive disease after living-related liver transplantation. Transplantation 2003; 76: 1007.